Who are Fusidic Acid 1% M/R Eye Drops's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fusidic-acid-1-m-r-eye-drops.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fusidic Acid 1% M/R Eye Drops — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fusidic Acid 1% M/R Eye Drops (Fusidic Acid 1% M/R Eye Drops) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bacterial protein synthesis inhibitor / Antibiotic. Area: Ophthalmology / Infectious Disease.

marketed Bacterial protein synthesis inhibitor / Antibiotic Elongation factor G (EF-G) Ophthalmology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fusidic Acid 1% M/R Eye Drops (Fusidic Acid 1% M/R Eye Drops) — Barzilai Medical Center. Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G, preventing bacterial growth in ocular infections.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fusidic Acid 1% M/R Eye Drops TARGET	Fusidic Acid 1% M/R Eye Drops	Barzilai Medical Center	marketed	Bacterial protein synthesis inhibitor / Antibiotic	Elongation factor G (EF-G)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bacterial protein synthesis inhibitor / Antibiotic class)

Barzilai Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fusidic Acid 1% M/R Eye Drops — Competitive Intelligence Brief. https://druglandscape.com/ci/fusidic-acid-1-m-r-eye-drops. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab